Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 8/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | DHPS | P49366 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16343945 | 0.89 | LIPE (0.47) | LIPENR1H4PPARGNPC1ALDH1A1 | |
| SCHEMBL15964508 | 0.83 | LIPE (0.47) | LIPENR1H4PPARGNPC1ALDH1A1 | |
| SCHEMBL17012560 | 0.83 | LIPE (0.34) | LIPE | |
| SCHEMBL3720444 | 0.79 | LIPE (0.46) | LIPENPC1ALDH1A1RAB9AMAPT | |
| SCHEMBL15956659 | 0.79 | LIPE (0.43) | LIPEMAPTDHPSCA1CA2 | |
| SCHEMBL3705786 | 0.78 | LIPE (0.42) | LIPE | |
| SCHEMBL3872642 | 0.77 | LIPE (0.44) | LIPENR1H4PPARGMAPTDHPS | |
| SCHEMBL15957110 | 0.77 | LIPE (0.45) | LIPENR1H4MAPTRECQLDHPS | |
| SCHEMBL104612 | 0.76 | RAB9A (0.54) | LIPENR1H4PPARGNPC1ALDH1A1 | |
| SCHEMBL29709477 | 0.76 | RAB9A (0.54) | LIPENR1H4PPARGNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233111-B2 | Pyrrolo pyrimidine derivatives | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| US-9233111-B2 | Pyrrolo pyrimidine derivatives | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| EP-2729466-B1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-20140243306-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-20140243306-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243306-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | BTK, LCK, ZAP70 | LIPE 4738/4885NR1H4 2847/4885PPARG 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.